A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.
Inclusion Criteria
- A diagnosis of Alzheimer's disease (AD) in accordance with the 2024 Alzheimer's Association criteria with one of the following confirmations of AD pathology:
i) Historical evidence of AD diagnosis with amyloid positron emission tomography (PET), AÎČ42/40 ratio in CSF, pTau181/AÎČ42 ratio in CSF or pTau217/AÎČ42 ratio in plasma using an Health Authority (HA)-authorized diagnostic assay.
ii) If no historical evidence available:
A. A plasma biomarker will be assessed for eligibility if allowed per regulatory requirements. The test cutoff(s) will be based on diagnostic use approval.
B. If a plasma biomarker assay cannot be used or if the assay result is inconclusive, conduct one the following:
Amyloid PET.
AÎČ42/40 ratio or pTau181/AÎČ42 ratio in CSF using an HA-authorized diagnostic assay.
Mini-Mental State Examination (MMSE) score of †24 at Screening (Visit 1).
Have an identified caregiver who has sufficient contact (approximately 8 hours over a week) and is willing to:
i) Attend all visits and report on participant's status.
ii) Oversee participant compliance with medication and study procedures.
iii) Participate in the study assessments and provide informed consent to participate in the study.
Exclusion Criteria
- Medical Conditions.
i) Agitation symptoms that are primarily attributable to a condition other than the AD causing the dementia.
ii) History of bipolar disorder, schizophrenia, or schizoaffective disorder.
iii) History of (or at high risk for) urinary retention, gastric retention, or narrow-angle glaucoma as evaluated by the Investigator.
iv) Risk of suicidal behavior during the study as determined by the Investigator's clinical assessment and/or C-SSR.
- Prior/Concomitant Therapy.
i) Recent history of receiving monoamine oxidase inhibitors, anticonvulsants (eg, lamotrigine, divalproex), mood stabilizers (eg, lithium), tricyclic antidepressants (eg, imipramine, desipramine), or any other psychoactive medications except for as needed anxiolytics (eg, lorazepam).
A. Selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors taken at a stable dose for at least 8 weeks prior to Screening (Visit 1) may be permitted.
B. Trazodone may be used as a hypnotic or for agitation if started at least 8 weeks prior to Screening (Visit 1).
Note: Mirtazapine may be used as a hypnotic if started at least 8 weeks prior to Screening (Visit 1).
- Other protocol-defined Inclusion/Exclusion criteria apply.
Clinical.Trials@bms.com855-907-3286
Chandler, Arizona 85224, United States
480-382-7909
Ciudad Autonoma de Buenos Aires, Buenos Aires 1058, Argentina
541143000000
Buenos Aires, 1133, Argentina
Toulouse, Haute-Garonne 31000, France
Lille, 59037, France
Paris, 75010, France
Strasbourg, 67091, France
Ramat Gan, Central District 5262000, Israel
Petch Tikva, IL 49100, Israel
Rishon Le'Tzion, 7590653, Israel
Rome, Lazio 00185, Italy
Poznan, Greater Poland Voivodeship 61-485, Poland
Deagu, Taegu-KwangyÇkshi 41404, South Korea
82532003299
Smila, Cherkasy Oblast 20708, Ukraine
Dnipro, Dnipropetrovsk Oblast 49115, Ukraine
Skarzhyntsi, Khmelnytskyi Oblast 32120, Ukraine
380672624158
Hlevakha, Kyiv Oblast 08631, Ukraine
Lviv, Lviv Oblast 79021, Ukraine
Oleksandrivka, Odesa Oblast 67513, Ukraine
Vinnytsia, Vinnytsia Oblast 21037, Ukraine
Hlevakha, 08631, Ukraine
Kropyvnytskyi, 25491, Ukraine
Kyiv, 04080, Ukraine
Poltava, 36013, Ukraine
Preston, Lancashire PR2 9HT, United Kingdom
Chertsey, Surrey KT16 9AU, United Kingdom
305-819-2909
+61736460818
3057518626x2403
813-251-1800
404-382-8660
413-214-3546
601-606-0911
702-637-3223
718-619-4403
718-407-0225
252-515-0050
513-769-2767
972-782-2405
949-491-0710
972-777-6956
210-567-8229
425-899-3123
5491144455572
+5491157934078
+5493515993881
5493516858696
+5493516508068
54-261-9-155861633
+56982945977
56940920180
005622910 2853
5655240334
00420723060809
+420224434700
+420605809745
+420603198029
+420495835233
420777242101
420604236033
0320446021
+555058262
33467336029
+33388115844
36206207623
+36 20 825 0367
0526666570
+39081743741
3988888888x88
390633775630
+39 3928537305
+39335435387
+393930406304
+39 0630154859
+48604116632
0048698619497
+48518424470
+48505723735
+48 697 777 777
1-787-679-3324
7874035534
+82328902080
+82-2-2072-2193
+821045057561
+82324603346
0000000000
8228702462
82216617575
380473321979
+380675658914
380506480750
+380-67-6702827
+380679920420
+380679605672
+380504122719
+380505641035
+380503847048
+380-67-7791518
+380 67 379 7848
+380502523300
+44 1772 522972
+44 300 555 5222
+44 800 731 2864
+44 141 948 0206
+44 1208 251 300
+44 114 226 1600
+44 1902 444141